---
title: "SINO BIOPHARM won the \"Company of the Year\" award at the 2025 BayHelix Awards"
description: "SINO BIOPHARM won the \"Company of the Year\" award at the 2025 BayHelix Awards for its acquisition of Li Xin Pharmaceutical. This approximately USD 1 billion merger and acquisition deal has granted it "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262716650.md"
published_at: "2025-10-25T08:13:01.000Z"
---

# SINO BIOPHARM won the "Company of the Year" award at the 2025 BayHelix Awards

> SINO BIOPHARM won the "Company of the Year" award at the 2025 BayHelix Awards for its acquisition of Li Xin Pharmaceutical. This approximately USD 1 billion merger and acquisition deal has granted it 8 clinical projects, marking significant progress for domestic pharmaceutical companies in China's biotechnology ecosystem

According to reporters at the BioCentury-BayHelix 12th China Healthcare Summit, China National Pharmaceutical Group (SINO BIOPHARM) has won the 2025 BayHelix Awards "Company of the Year" award, thanks to its groundbreaking acquisition of Lixin Pharmaceutical for approximately $1 billion in July this year. BioCentury stated that this year, SINO BIOPHARM completed a nearly $1 billion merger with Lixin Pharmaceutical, a rare instance of a domestic pharmaceutical company acquiring a local innovator in China's increasingly mature biotechnology ecosystem. This transaction enabled SINO BIOPHARM to gain eight clinical projects at once

### Related Stocks

- [01177.HK - SINO BIOPHARM](https://longbridge.com/en/quote/01177.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 早盤趨勢｜中國生物製藥回踩低點，反彈窗口會否開啓？ | 中國生物製藥（1177.HK）近期股價持續低位震盪整理，日線呈現小幅陰陽交替，整體重心下移。近幾個交易日，股價回踩至前低區間附近，成交量持續萎縮，場內增量資金觀望情緒濃厚。從技術面看，MACD 指標依舊死叉，綠柱顯著，短線多空分歧較大。 基 | [Link](https://longbridge.com/en/news/274491341.md) |
| 早盤趨勢｜中國生物製藥回踩低點，反彈窗口會否開啓？ | 中國生物製藥（1177.HK）近期股價持續低位震盪整理，日線呈現小幅陰陽交替，整體重心下移。近幾個交易日，股價回踩至前低區間附近，成交量持續萎縮，場內增量資金觀望情緒濃厚。從技術面看，MACD 指標依舊死叉，綠柱顯著，短線多空分歧較大。 基 | [Link](https://longbridge.com/en/news/274496124.md) |
| Select 醫藥控股｜10-K：2025 財年營收 54.53 億美元超過預期 |  | [Link](https://longbridge.com/en/news/276384073.md) |
| 忘掉 AI 股票：這家制藥巨頭正在通過 AI 主導藥物研發 | 而且還有多種方式可以將這項技術變現 | [Link](https://longbridge.com/en/news/276017486.md) |
| Madrigal 製藥｜8-K：2025 財年 Q4 營收 3.21 億美元超過預期 |  | [Link](https://longbridge.com/en/news/276330350.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.